255 related articles for article (PubMed ID: 18711309)
1. Cancers after renal transplantation: multicenter experience.
Harzallah K; Abderrahim E; Chareffedine K; Yeich S; Belhadj R; Skhiri H; Younsi F; Abdallah TB; Abdelletif A; Hachicha J; Hmida J; El May M; Khedr A; Manaa J
Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):825-30. PubMed ID: 18711309
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
3. Genitourinary tumor following kidney transplantation: a multicenter study.
Einollahi B; Simforoosh N; Lessan-Pezeshki M; Basiri A; Nafar M; Pour-Reza Gholi F; Firouzan A; Ahmadpour P; Makhdomi K; Ghafari A; Taghizadeh A; Tayebi Khosroshahi H
Transplant Proc; 2009 Sep; 41(7):2848-9. PubMed ID: 19765454
[TBL] [Abstract][Full Text] [Related]
4. A population-based study of skin cancer incidence and prevalence in renal transplant recipients.
Moloney FJ; Comber H; O'Lorcain P; O'Kelly P; Conlon PJ; Murphy GM
Br J Dermatol; 2006 Mar; 154(3):498-504. PubMed ID: 16445782
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases.
Yaich S; Charfeddine K; Zaghdane S; El Aoud N; Jarraya F; Kharrat M; Hachicha J
Transplant Proc; 2012 Nov; 44(9):2824-6. PubMed ID: 23146533
[TBL] [Abstract][Full Text] [Related]
6. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation.
Fraile P; García-Cosmes P; Martín P; García-Bernalt V; Tabernero JM
Transplant Proc; 2009; 41(6):2433-4. PubMed ID: 19715943
[TBL] [Abstract][Full Text] [Related]
7. Early de novo malignancies after kidney transplantation.
Veroux M; Puliatti C; Fiamingo P; Cappello D; Macarone M; Puliatti D; Vizcarra D; Gagliano M; Veroux P
Transplant Proc; 2004 Apr; 36(3):718-20. PubMed ID: 15110643
[TBL] [Abstract][Full Text] [Related]
8. Cancer in renal transplant recipients.
Sakellariou G; Memmos D; Alexopoulos E; Tsobanelis T; Sinakos Z; Papadimitriou M
Cancer Detect Prev; 1986; 9(3-4):389-93. PubMed ID: 3527417
[TBL] [Abstract][Full Text] [Related]
9. [Renal transplantation and malignancies: A single-centre experience (25 years)].
Stefoni S; Scolari MP; Sestigiani E; Faenza A; Campieri C; Buscaroli A; Liviano D'Arcangelo G; D'Addio F
G Ital Nefrol; 2002; 19(6):650-7. PubMed ID: 12508170
[TBL] [Abstract][Full Text] [Related]
10. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
12. Conversion to sirolimus in renal transplant patients with tumors.
Sánchez-Fructuoso A; Conesa J; Perez Flores I; Ridao N; Calvo N; Prats D; Rodríguez A; Barrientos A
Transplant Proc; 2006 Oct; 38(8):2451-2. PubMed ID: 17097964
[TBL] [Abstract][Full Text] [Related]
13. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.
Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS
Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824
[TBL] [Abstract][Full Text] [Related]
14. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation.
Aseni P; Vertemati M; De Carlis L; Sansalone CV; Bonacina E; Minola E; Oreste P; Vizzotto L; Rondinara G
Pathol Int; 2006 Nov; 56(11):712-5. PubMed ID: 17040297
[TBL] [Abstract][Full Text] [Related]
15. De novo malignances in pediatric organ transplant recipients.
Penn I
Pediatr Transplant; 1998 Feb; 2(1):56-63. PubMed ID: 10084762
[TBL] [Abstract][Full Text] [Related]
16. Skin malignancies in renal transplant recipients: a Brazilian center registry.
Falsarella PM; Alves-Filho G; Mazzali M
Transplant Proc; 2008 Apr; 40(3):767-8. PubMed ID: 18455011
[TBL] [Abstract][Full Text] [Related]
17. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.
Zhou M; Zhu Y; Wang L; Wang Y; Fu S; Min Z
Clin Transpl; 2006; ():395-8. PubMed ID: 18365395
[TBL] [Abstract][Full Text] [Related]
18. Neoplastic skin lesions in Iranian renal transplant recipients: the role of immunosuppressive therapy.
Zamanian A; Farshchian M
J Drugs Dermatol; 2007 Jul; 6(7):703-6. PubMed ID: 17763593
[TBL] [Abstract][Full Text] [Related]
19. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of malignancy after transplantation in Chinese heart allograft recipients.
Hsu RB; Chen RJ; Chou NK; Ko WJ; Wang SS; Chu SH
Transpl Int; 2005 Mar; 18(3):283-8. PubMed ID: 15730487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
